Helia Robert-Ebadi

Dr. Helia Robert-Ebadi

Geneva University Hospitals and Faculty of Medicine, Geneva, Genève, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Thrombosis Research
Verified
Journal Article
Closed access
HRHelia Robert-Ebadi
Helia Robert-Ebadi
MRMarc Righini
Marc Righini

1 February 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MSMilou A.M. Stals
Milou A.M. Stals
TTToshihiko Takada
Toshihiko Takada
NKNoémie Kraaijpoel
Noémie Kraaijpoel
NENick van Es
Nick van Es
HBHarry R. Büller
Harry R. Büller
FKFrederikus A. Klok
Frederikus A. Klok
How diagnostic strategies for pulmonary embolism (PE) perform across clinical patient characteristics is unclear. In this individual-participant data meta-analysis, investigators pooled data from 2... Background: How diagnostic strategies for suspected pulmonary embolism (PE) perform in relevant patient subgroups defined by sex, age, cancer, and previous venous thromboembolism (VTE) is unknown. ...

23 June 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MBMarta Bellesini
Marta Bellesini
HRHelia Robert-Ebadi
Helia Robert-Ebadi
CCChristophe Combescure
Christophe Combescure
CDCristina Dedionigi
Cristina Dedionigi
GGGrégoire Le Gal
Grégoire Le Gal
MRMarc Righini
Marc Righini
Background The usefulness of D-dimer measurement to rule out venous thromboembolism (VTE) during pregnancy is debated. Aims We performed a systematic review and meta-analysis to investigate the safety of D-dimer to rule out acute VTE in pregnant women with suspected pulmonary embolism (PE) and/or deep vein thrombosis (DVT). Methods Two reviewers independently identified studies through Pubmed and Embase until June 2021, Week 1. We supplemented our search by manually reviewing reference lists of all retrieved articles, clinicalTrials.gov and reference literature. Prospective or retrospective studies in which a formal diagnostic algorithm was used to evaluate the ability of D-dimer to rule out VTE during pregnancy were eligible. Results We identified 665 references through systematic database and additional search strategies; 45 studies were retrieved in full, of which four were included, after applying exclusion criteria. Three studies were prospective, and one had a retrospective design. The three-month thromboembolic rate in pregnant women left untreated after a negative D-dimer was 1/312 (0.32%; 95% CI, 0.06-1.83). The pooled estimate values were 99.5% for sensitivity (95% CI, 95.0-100.0; I², 0%) and 100% for negative predictive value (95% CI, 99.19-100.0; I², 0%). The prevalence of VTE and the yield of D-dimer were 7.4% (95% CI, 3.8-12; I², 83%) and 34.2% (95% CI, 15.9-55.23; I², 89%) respectively. Conclusion Our results suggest that D-dimer allows to safely rule out VTE in pregnant women with suspected VTE and a disease prevalence consistent with a low/intermediate or unlikely pre-test probability.

23 June 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PEPaul L. Den Exter
Paul L. Den Exter
SWScott C. Woller
Scott C. Woller
HRHelia Robert-Ebadi
Helia Robert-Ebadi
CMCamila Masias
Camila Masias
PMPierre‐Emmanuel Morange
Pierre‐Emmanuel Morange
FKFrederikus A. Klok
Frederikus A. Klok
Patients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent recurrent VTE and death, which exposes them to an inherent increased risk of bleeding. Identification of patients at high risk of bleeding, and mitigating this risk, is an essential component of the immediate and long‐term therapeutic management of VTE. The bleeding risk can be estimated by either implicit judgment, weighing individual predictors (clinical variables or biomarkers), or by risk prediction tools developed for this purpose. Management of bleeding risk in clinical practice is, however, far from standardized. International guidelines are contradictory and lack clear and consistent guidance on the optimal management of bleeding risk. This report of the ISTH subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease summarizes the evidence on the prediction of bleeding in VTE patients. We systematically searched the literature and identified 34 original studies evaluating either predictors or risk prediction models for prediction of bleeding risk on anticoagulation in VTE patients. Based on this evidence, we provide recommendations for the standardized management of bleeding risk in VTE patients.

1 April 2009 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
HRHelia Robert-Ebadi
Helia Robert-Ebadi
GGGrégoire Le Gal
Grégoire Le Gal
MRMarc Righini
Marc Righini
Use of anticoagulants in elderly patients: practical recommendations Helia Robert-Ebadi, Grégoire Le Gal, Marc RighiniDivision of Angiology and Hemostasis (HRE, MR), Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland, and Department of Internal Medicine and Chest Diseases, EA 3878 (GETBO), Brest University Hospital, Brest, France (GLG) Elderly people represent a patient population at high thromboembolic risk, but also at high hemorrhagic risk. There is a general tendency among physicians to underuse anticoagulants in the elderly, probably both because of underestimation of thromboembolic risk and overestimation of bleeding risk. The main indications for anticoagulation are venous thromboembolism (VTE) prophylaxis in medical and surgical settings, VTE treatment, atrial fibrillation (AF) and valvular heart disease. Available anticoagulants for VTE prophylaxis and initial treatment of VTE are low molecular weight heparins (LMWH), unfractionated heparin (UFH) or synthetic anti-factor Xa pentasaccharide fondaparinux. For long-term anticoagulation vitamin K antagonists (VKA) are the first choice and only available oral anticoagulants nowadays. Assessing the benefit-risk ratio of anticoagulation is one of the most challenging issues in the individual elderly patient, patients at highest hemorrhagic risk often being those who would have the greatest benefit from anticoagulants. Some specific considerations are of utmost importance when using anticoagulants in the elderly to maximize safety of these treatments, including decreased renal function, co-morbidities and risk of falls, altered pharmacodynamics of anticoagulants especially VKAs, association with antiplatelet agents, patient education. Newer anticoagulants that are currently under study could simplify the management and increase the safety of anticoagulation in the future.Keywords: anticoagulation, elderly patients, venous thromboembolism, hemorrhagic risk, atrial fibrillation, thrombin inhibitors, factor Xa inhibitor

8 September 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
HRHelia Robert-Ebadi
Helia Robert-Ebadi
AEAntoine Elias
Antoine Elias
OSOlivier Sanchez
Olivier Sanchez
EMEmmanuelle Le Moigne
Emmanuelle Le Moigne
JSJeannot Schmidt
Jeannot Schmidt
MRMarc Righini
Marc Righini
Background The diagnosis of pulmonary embolism (PE) in pregnant women represents an ongoing challenge. As in the general population, the first step in pregnant women with suspected PE consists of assessing pre-test clinical probability (PTP). However, no dedicated clinical decision rule has been developed in this population. Objectives To propose a new version of the Geneva score adapted to pregnant women with suspected PE. Methods Data from a multicenter, prospective management outcome study including 395 women with suspected PE, in whom PTP was assessed using the Geneva score, were used. We first removed items which were present in none of the patients (cancer, age > 65 years). ROC curve analysis was then performed for quantitative variables and the optimal threshold defined. The obtained pregnancy-adapted Geneva score (PAG score) comprised 7 items, including an age 40 years or older and a heart rate > 110 beats per minute. Results The PAG score showed a high discriminative power to identify patients with a low, intermediate or high PTP, associated with increasing prevalence of PE, 2.3%, 11.6% and 61.5%, respectively. The ROC curves showed an area under the curve of 0.795 for the PAG score compared to 0.684 for the Geneva score. Conclusion In pregnant women with suspected PE, the PAG score shows a high discriminative power to identify patients at low, intermediate or high PTP. It has the strength of being a fully objective decision rule, is clinically relevant, easy to compute, and should now be tested in a prospective outcome study.